Ram, I could give you a list as long as your arm of biotech companies who have been around for a similar time frame as ADO, without ever turning a penny. It is par for the course.
One can sit back and armchair criticise, or alternatively come to the realisation that it is an extremely difficult game with few eventual winners. But boy, when one wins, the wait is often more than well worth it.
IMO, it is a credit to this company and its tech that it is still in there with a realistic reward/risk chance of cracking it. (At least better than most.)
Instead of hanging around here like a bad smell, recounting ad nauseum the same bleak picture, wouldn't you be better off picking some other long term losers and bang on about them? There is always a big field to choose from.
[P.S. Most such companies retain their coterie of happy clappers. It ain't unusual, so why the focus here?]
